Table 2.
Baseline demographics and clinical characteristics of matched study cohorts.
| Panel A – Relapse outcome | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Characteristic | N | DMF (NTD) | OCR (OPERA) | FTY (NTD) | OCR (OPERA) | GA (NTD) | OCR (OPERA) | NTZ (NTD) | OCR (OPERA) | IFN β-1a (NTD) | OCR (OPERA) | TERI (NTD) | OCR (OPERA) |
| 167 | 167 | 185 | 185 | 169 | 169 | 130 | 130 | 118 | 118 | 111 | 111 | ||
| Age (years) | Mean (SD) | 39.6 (10.1) | 39.1 (8.5) | 38.3 (10.0) | 38.5 (9.3) | 37.4 (11.0) | 37.9 (9.1) | 37.0 (9.9) | 37.3 (9.1) | 38.1 (10.6) | 36.8 (8.3) | 42.5 (10.5) | 41.1 (8.8) |
| EDSS | Mean (SD) | 2.4 (1.6) | 2.4 (1.2) | 2.9 (1.6) | 2.9 (1.3) | 2.2 (1.6) | 2.2 (1.1) | 2.8 (1.7) | 2.8 (1.3) | 2.2 (1.5) | 2.2 (1.2) | 2.5 (1.8) | 2.3 (1.1) |
| Previous treatment, n (%) | No | 93 (55.7) | 84 (50.3) | 41 (22.2) | 44 (23.8) | 113 (66.9) | 108 (63.9) | 33 (25.4) | 28 (21.5) | 85 (72.0) | 90 (76.3) | 66 (59.5) | 62 (55.9) |
| Yes | 74 (44.3) | 83 (49.7) | 144 (77.8) | 141 (76.2) | 56 (33.1) | 61 (36.1) | 97 (74.6) | 102 (78.5) | 33 (28.0) | 28 (23.7) | 45 (40.5) | 49 (44.1) | |
| Relapses in year prior to therapy | Mean (SD) | .9 (.6) | .9 (.4) | 1.1 (.7) | 1.1 (.6) | 1.0 (.6) | 1.0 (.4) | 1.0 (.7) | 1.1 (.6) | .9 (.6) | .9 (.5) | .8 (.6) | .9 (.5) |
| Sex, n (%) | Male | 49 (29.3) | 57 (34.1) | 55 (29.7) | 54 (29.2) | 40 (23.7) | 47 (27.8) | 40 (30.8) | 32 (24.6) | 32 (27.1) | 32 (27.1) | 34 (30.6) | 32 (28.8) |
| Female | 118 (70.7) | 110 (65.9) | 130 (70.3) | 131 (70.8) | 129 (76.3) | 122 (72.2) | 90 (69.2) | 98 (75.4) | 86 (72.9) | 86 (72.9) | 77 (69.4) | 79 (71.2) | |
| Time since symptom onset (years) | Mean (SD) | 8.9 (8.4) | 7.9 (6.0) | 8.4 (6.8) | 8.1 (5.5) | 5.9 (7.2) | 6.5 (6.1) | 8.6 (6.9) | 8.7 (5.5) | 6.9 (8.4) | 6.3 (5.9) | 8.8 (7.9) | 8.1 (6.0) |
| Gd+ lesions, n (%) | Present | 58 (34.7) | 58 (34.7) | 69 (37.3) | 72 (38.9) | 59 (34.9) | 66 (39.1) | 58 (44.6) | 53 (40.8) | 43 (36.4) | 53 (44.9) | 29 (26.1) | 30 (27.0) |
| Not present | 109 (65.3) | 109 (65.3) | 116 (62.7) | 113 (61.1) | 110 (65.1) | 103 (60.9) | 72 (55.4) | 77 (59.2) | 75 (63.6) | 65 (55.1) | 82 (73.9) | 81 (73.0) | |
DMF, dimethyl fumarate; EDSS, Expanded Disability Status Scale; FTY, fingolimod; GA, glatiramer acetate; Gd+, gadolinium-enhancing; IFN β-1a, interferon β-1a; NTD, NeuroTransData registry; NTZ, natalizumab; OCR, ocrelizumab; SD, standard deviation; TERI, teriflunomide.